HCW-9218 is a fusion protein commercialized by HCW Biologics, with a leading Phase II program in Metastatic Pancreatic Cancer. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of HCW-9218’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for HCW-9218 is expected to reach an annual total of $24 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
HCW-9218 is under development for the treatment of metastatic pancreatic cancer, other solid tumors including refractory breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes and idiopathic pulmonary fibrosis, liver cancer, and non-alcoholic fatty liver disease (NAFLD). It is administered through subcutaneous route. The drug candidate is a heterodimeric, bifunctional fusion protein complex TGF-beta combined with IL-15 and is developed based on TOBI (Tissue factor based fusion) platform which acts by targeting transforming growth factor beta (TGF-beta).
HCW Biologics Overview
HCW Biologics is a developer of immunotherapy platforms to activate the immune system in order to disrupt the links between aging and disease. HCW Biologics is headquartered in Miramar, Florida, the US.
The company reported revenues of (US Dollars) US$6.7 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$15.1 million in FY2022, compared to an operating loss of US$12.8 million in FY2021. The net loss of the company was US$14.9 million in FY2022, compared to a net loss of US$12.9 million in FY2021.
For a complete picture of HCW-9218’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.